Junshi Biosciences: Revenue growth of 28.23% in 2025, with core product Tuoyi®'s domestic market sales revenue increasing by approximately 37.72%

Recently, Junshi Biosciences announced that preliminary calculations of its main financial data for 2025 show the company’s total operating revenue is 2.498 billion yuan, a year-on-year increase of 28.23%. During the reporting period, net profit attributable to the parent company was approximately a loss of 874 million yuan, an improvement compared to a loss of 1.281 billion yuan in the same period last year.

The announcement mentioned that the company’s core product, Toripalimab Injection (Tuoyi®), saw a significant year-on-year increase in sales revenue of about 37.72% in the domestic market. As of the disclosure date, all approved indications of Tuoyi® in mainland China have been included in the national medical insurance catalog, and the product has received approval for listing in multiple countries and regions worldwide. The company implemented an equity incentive plan, which increased stock-based compensation expenses, but through strengthened expense control and resource focus, the net loss attributable to the parent was significantly narrowed.

(Junshi Biosciences Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare